Make a difference: Share your views on proposed changes to standards, regulations, policies and legislation.

 

We need to hear from you

As a leader in primary health care, the College is often approached by government and health organisations for its views on current standard, regulation, policy and legislation changes.

Your feedback, in any form, is essential in helping us develop our submissions to government bodies and health organisations.

Occasionally the College will not respond to consultations that are outside our area of expertise. However, even if the College is not responding on your behalf, we do encourage you to provide your feedback directly to the organisation.

If you would like to subscribe to consultation topics about your areas of special interest, please register with the professional interest groups in the 'my details' page in the Dashboard.

Further information on College consultations

Further information for members on proposed codeine classification changes - Medicines Classification Committee (MCC) 

In response to classification changes agreed in Australia in 2016 the Medicines Classification Committee (MCC) of Medsafe considered whether NZ should harmonise with Australia in making medicines containing codeine no longer available without a prescription. 
In 2017 the MCC recommended that;

• Medicines containing codeine as the sole active ingredient ≤15 mg per solid dosage unit in packs of not more than 3 days’ supply with a maximum daily dose of not more than 90 mg for oral use in adults and children for analgesia be classified as restricted medicines,
• All other medicines containing codeine would be classified as prescription medicines.

This recommendation has been sent back to the MCC on the grounds that the MCC is expected to recommend on whether to harmonise or not, rather than recommend an alternative option. In addition, the alternative option recommended would require a change to both the Medicines Regulations and the Misuse of Drugs Regulations which would take some time. 

The MCC is now deciding on which of the three options below to recommend. If the MCC make a recommendation that is not one of the options outlined below, the recommendation must go out for
a consultation again for a future meeting.

Current classification

Future Classification Options

Timeframes

  • Codeine when in combination with another active ingredient in cough and cold medicines is classified as a pharmacy-only medicine,
  • Codeine when in combination with another active ingredient for analgesia is classified as a restricted medicine,
  • All other medicines containing codeine are classified as prescription medicines

A. To retain the Status Quo

  • Codeine when in combination with another active ingredient in cough and cold medicines remains classified as a pharmacy-only medicine,
  • Codeine when in combination with another active ingredient for analgesia remains classified as a restricted medicine,
  • All other medicines containing codeine remain classified as prescription medicines

B. To harmonise with Australia

  • All medicines containing codeine would be classified as prescription medicines

C. To reclassify codeine as per the recommendation made at the 59th meeting of the MCC

  • Medicines containing codeine as the sole active ingredient ≤15 mg per solid dosage unit in packs of not more than 3 days’ supply with a maximum daily dose of not more than 90 mg for oral use in adults and children for analgesia be classified as restricted medicines,
  • All other medicines containing codeine would be classified as prescription medicines.

A This recommendation could be implemented as per the standard time frames (four weeks following publication of the minutes).

 

B This recommendation could be implemented as per the standard time frames.

 

C This recommendation would require a change to both the Medicines Regulations and the Misuse of Drugs Regulations. The timeframe for this is uncertain.

 

 

 


Other consultations

The College does not intend to make submissions on these consultations, however individual GPs may wish to respond.

  • No current consultations

PHARMAC consultations

PHARMAC regularly conducts consultations on their processes and funding decisions. See the list of PHARMAC consultations.

The New Zealand government agency PHARMAC makes decisions about which vaccines, community and cancer medicines District Health Boards (DHBs) fund.